HRP20221474T1 - Cjepiva protiv virusa hepatitisa b - Google Patents
Cjepiva protiv virusa hepatitisa b Download PDFInfo
- Publication number
- HRP20221474T1 HRP20221474T1 HRP20221474TT HRP20221474T HRP20221474T1 HR P20221474 T1 HRP20221474 T1 HR P20221474T1 HR P20221474T T HRP20221474T T HR P20221474TT HR P20221474 T HRP20221474 T HR P20221474T HR P20221474 T1 HRP20221474 T1 HR P20221474T1
- Authority
- HR
- Croatia
- Prior art keywords
- protein
- hbv
- nucleotide sequence
- viral vector
- arenavirus
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims 5
- 241000700721 Hepatitis B virus Species 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 claims 29
- 239000002773 nucleotide Substances 0.000 claims 28
- 125000003729 nucleotide group Chemical group 0.000 claims 28
- 102000004169 proteins and genes Human genes 0.000 claims 28
- 230000000890 antigenic effect Effects 0.000 claims 26
- 239000012634 fragment Substances 0.000 claims 25
- 239000013603 viral vector Substances 0.000 claims 24
- 241000712891 Arenavirus Species 0.000 claims 19
- 102100031673 Corneodesmosin Human genes 0.000 claims 13
- 101710139375 Corneodesmosin Proteins 0.000 claims 13
- 230000004927 fusion Effects 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 12
- 208000015181 infectious disease Diseases 0.000 claims 11
- 230000002458 infectious effect Effects 0.000 claims 11
- 108700026244 Open Reading Frames Proteins 0.000 claims 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 241000712899 Lymphocytic choriomeningitis mammarenavirus Species 0.000 claims 5
- 102000003886 Glycoproteins Human genes 0.000 claims 4
- 108090000288 Glycoproteins Proteins 0.000 claims 4
- 230000002068 genetic effect Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 239000002245 particle Substances 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 230000005867 T cell response Effects 0.000 claims 3
- 239000002299 complementary DNA Substances 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- 230000002950 deficient Effects 0.000 claims 2
- 230000005923 long-lasting effect Effects 0.000 claims 2
- 230000007774 longterm Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 238000001890 transfection Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims 1
- 241000585245 Methylophaga aminisulfidivorans Species 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000002672 hepatitis B Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000012423 maintenance Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/10011—Arenaviridae
- C12N2760/10041—Use of virus, viral particle or viral elements as a vector
- C12N2760/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Claims (16)
1. Zarazni virusni vektor arenavirusa, pri čemu je otvoreni okvir za čitanje arenavirusa uklonjen i zamijenjen nukleotidnom sekvencom odabranom iz skupine koju čine:
a. nukleotidna sekvenca koja kodira HBV HBc protein ili njegov antigenski fragment;
b. nukleotidna sekvenca koja kodira fuziju HBV HBs i HBc proteina ili njihovih antigenskih fragmenata; i
c. nukleotidna sekvenca koja kodira HBV pre-S2/S protein ili njegov antigenski fragment;
pri čemu je virusni vektor sposoban izazvati T-stanični odgovor protiv HBV HBc proteina, fuzije HBV HBs i HBc proteina, HBV pre-S2/S proteina, ili njihovog antigenskog fragmenta.
2. Virusni vektor prema patentnom zahtjevu 1, pri čemu
(i) HBc protein ili njegov antigenski fragment obuhvaća aminokiselinsku sekvencu koja je 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, ili 100% istovjetna aminokiselinskoj sekvenci kodiranoj nukleotidnom sekvencom SEQ ID NO: 2;
(ii) fuzija HBV HBs i HBc proteina ili njihovih antigenskih fragmenata obuhvaća aminokiselinsku sekvencu koja je 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% ili 100% istovjetna aminokiselinskoj sekvenci kodiranoj nukleotidnom sekvencom SEQ ID NO: 3; ili
(iii) pre-S2/S protein ili njegov antigenski fragment obuhvaća aminokiselinsku sekvencu koja je 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89 %, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, ili 100% istovjetna aminokiselinskoj sekvenci kodiranoj nukleotidnom sekvencom SEQ ID NO: 1.
3. Virusni vektor prema patentnom zahtjevu 1, koji obuhvaća najmanje dvije ili najmanje tri od:
a. nukleotidne sekvence koja kodira HBV HBc protein ili njegov antigenski fragment;
b. nukleotidne sekvence koja kodira fuziju HBV HBs i HBc proteina ili njihovih antigenskih fragmenata; i
c. nukleotidne sekvence koja kodira HBV pre-S2/S protein ili njegov antigenski fragment;
izborno pri čemu ekspresija nukleotidnih sekvenci proizvodi antigenski proteinski kompleks koji izaziva veće titre neutralizirajućih protutijela nego ekspresija komponenti proteinskog kompleksa pojedinačno.
4. Virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 3, pri čemu je arenavirus:
(i) virus limfocitnog koriomeningitisa;
(ii) replikacijski defektan i modificiran da sadrži genom sa sposobnošću amplificiranja i izražavanja svoje genetske informacije u zaraženim stanicama, ali bez sposobnosti proizvodnje daljnjih zaraznih čestica potomstva u normalnim, genetičkim nemodificiranim stanicama;
(iii) bi-segmentiran i replikacijski defektan; ili
(iv) trosegmentiran i replikacijski sposoban.
5. Virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je otvoreni okvir za čitanje koji kodira glikoprotein (GP) arenavirusa izbrisan ili funkcionalno inaktiviran.
6. Virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 5, pri čemu genomska informacija kodira zarazni virusni vektor arenavirusa koji je dobiven iz virusa limfocitnog koriomeningitisa ili virusa Pichinde, pri čemu je izborno virus limfocitnog koriomeningitisa soj klon 13 virusa limfocitnog koriomeningitisa ili soj MP virusa limfocitnog koriomeningitisa.
7. Virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 6, pri čemu virusni vektor sadrži genomski segment, pri čemu genomski segment obuhvaća:
(i) nukleotidnu sekvencu koja je najmanje 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, ili 100% istovjetna sekvenci nukleotida 1639 do 3315 SEQ ID NO: 11 ili nukleotida 1640 do 3316 SEQ ID NO: 12; ili
(ii) nukleotidnu sekvencu koja kodira produkt ekspresije čija je aminokiselinska sekvenca najmanje 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% ili 100% istovjetna aminokiselinskoj sekvenci kodiranoj nukleotidama 1639 do 3315 SEQ ID NO: 11 ili nukleotidama 1640 do 3316 SEQ ID NO: 12.
8. Virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu na rast ili zaraznost arenavirusa ne utječe nukleotidna sekvenca.
9. Virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 8, pri čemu je arenavirus virusni vektor zaraznog replikacijski defektnog arenavirusa modificiran da sadrži genom sa sposobnošću amplificiranja i izražavanja svoje genetske informacije u zaraženim stanicama, ali bez sposobnosti proizvodnje daljnjih zaraznih čestica potomstva u normalnim, genetički nemodificiranim stanicama, i pri čemu primjena virusnog vektora arenavirusa subjektu izaziva dugotrajni imunološki odgovor protiv HBV HBc proteina, fuzije HBV HBs i HBc proteina, HBV pre-S2/S proteina ili njihovog antigenskog fragmenta, izborno pri čemu
(i) dugotrajni imunološki odgovor inducira mjerljivi titar protutijela protiv HBV HBc proteina, fuzije HBV HBs i HBc proteina, HBV pre-S2/S proteina ili njegovog antigenskog fragmenta; ili
(ii) dugotrajni imunološki odgovor inducira mjerljivi titar protutijela protiv HBV HBc proteina, fuzije HBV HBs i HBc proteina, HBV pre-S2/S proteina ili njegovog antigenskog fragmenta barem minimalno 4 tjedna;
izborno pri čemu dugotrajni imunološki odgovor povećava titar protutijela protiv HBV HBc proteina, fuzije HBV HBs i HBc proteina, HBV pre-S2/S proteina ili njihovog antigenskog fragmenta za najmanje 100%, za najmanje 200%, za najmanje 300%, za najmanje 400%, za najmanje 500%, ili za najmanje 1000%.
10. Farmaceutski pripravak, imunogeni pripravak ili cjepivo koje sadrži virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 9 i farmaceutski prihvatljiv nosač.
11. Virusni vektor kako je definiran u bilo kojem od patentnih zahtjeva 1 do 9, ili farmaceutski pripravak, imunogeni pripravak, ili cjepivo kako je definirano u patentnom zahtjevu 10, za upotrebu u postupku liječenja ili prevencije infekcije virusom hepatitisa B kod pacijenta.
12. Izolirana nukleinska kiselina, pri čemu nukleinska kiselina sadrži genomski segment arenavirusa, pri čemu je jedan otvoreni okvir za čitanje genomskog segmenta izbrisan ili funkcionalno inaktiviran i pri čemu se genomski segment sastoji se od jedne ili više:
a. nukleotidne sekvence koja kodira HBV HBc protein ili njegov antigenski fragment;
b. nukleotidne sekvence koja kodira fuziju HBV HBs i HBc proteina ili njihovih antigenskih fragmenata; ili
c. nukleotidne sekvence koja kodira HBV pre-S2/S protein ili njegov antigenski fragment;
pri čemu virusni vektor obuhvaća genomski segment arenavirusa sposoban izazvati T-stanični odgovor protiv HBV HBc proteina, fuzije HBV HBs i HBc proteina, HBV pre-S2/S proteina, ili njihovog antigenskog fragmenta, izborno pri čemu je genomski segment kratki segment, pri čemu je otvoreni okvir za čitanje koji kodira glikoprotein (GP) izbrisan.
13. cDNK genomskog segmenta arenavirusa kako je definirano u patentnom zahtjevu 12.
14. In vitro metoda za stvaranje zaraznog replikacijski defektnog virusnog vektora arenavirusa, koja obuhvaća:
a. transfekciju cDNK prema patentnom zahtjevu 13 u stanicu domaćina;
b. održavanje stanice domaćina u uvjetima pogodnim za stvaranje virusa; i
c. sakupljanje zaraznog replikacijski defektnog virusnog vektora arenavirusa;
pri čemu stanica domaćina izražava otvoreni okvir čitanja genomskog segmenta koji je izbrisan ili funkcionalno inaktiviran;
izborno pri čemu metoda dalje uključuje korak a. transfekciju u stanicu domaćina: cDNK drugog genomskog segmenta arenavirusa, nukleinske kiseline koja sadrži otvoreni okvir čitanja (ORF) L proteina i/ili nukleinske kiseline koja sadrži ORF NP-a.
15. Farmaceutski pripravak koji sadrži prvi zarazni virusni vektor replikacijski defektnog arenavirusa modificiranog da sadrži genom sa sposobnošću amplificiranja i izražavanja svoje genetske informacije u zaraženim stanicama, ali bez sposobnosti proizvodnje daljnjih zaraznih čestica potomstva u normalnim, genetički nemodificiranim stanicama, pri čemu se jedan otvoreni okvir za čitanje arenavirusa uklanja i zamjenjuje prvom nukleotidnom sekvencom odabranom iz skupine koja se sastoji od:
a. nukleotidne sekvence koja kodira HBV HBc protein ili njegov antigenski fragment;
b. nukleotidne sekvence koja kodira fuziju HBV HBs i HBc proteina ili njihovih antigenskih fragmenata; i
c. nukleotidne sekvence koja kodira HBV pre-S2/S protein ili njegov antigenski fragment;
i drugi je zarazni virusni vektor, replikacijski defektnog arenavirusa modificiran da sadrži genom sa sposobnošću amplificiranja i izražavanja svoje genetske informacije u zaraženim stanicama, ali bez sposobnosti proizvodnje daljnjih zaraznih čestica potomstva u normalnim, genetički nemodificiranim stanicama, pri čemu se jedan otvoreni okvir za čitanje arenavirusa uklanja i zamjenjuje drugom nukleotidnom sekvencom odabranom iz skupine koja se sastoji od:
a. nukleotidne sekvence koja kodira HBV HBc protein ili njegov antigenski fragment;
b. nukleotidne sekvence koja kodira fuziju HBV HBs i HBc proteina ili njihovih antigenskih fragmenata; i
c. nukleotidne sekvence koja kodira HBV pre-S2/S protein ili njegov antigenski fragment;
pri čemu su prva i druga nukleotidna sekvenca različite; pri čemu su prvi virusni vektor i drugi virusni vektor sposobni izazvati T-stanični odgovor protiv HBV HBc proteina, fuzije HBV HBs i HBc proteina, HBV pre-S2/S proteina ili njihovog antigenskog fragmenta.
16. Virusni vektor prema bilo kojem od patentnih zahtjeva 1 do 9, ili farmaceutski pripravak, imunogeni pripravak ili cjepivo prema patentnom zahtjevu 10, ili farmaceutski pripravak prema patentnom zahtjevu 15, pri čemu je virusni vektor, farmaceutski pripravak, imunogeni pripravak ili cjepivo pogodno za intramuskularnu primjenu ili intravenoznu primjenu.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250639P | 2015-11-04 | 2015-11-04 | |
| EP16791573.5A EP3371316B1 (en) | 2015-11-04 | 2016-11-03 | Vaccines against hepatitis b virus |
| PCT/EP2016/076591 WO2017076988A1 (en) | 2015-11-04 | 2016-11-03 | Vaccines against hepatitis b virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20221474T1 true HRP20221474T1 (hr) | 2023-01-06 |
Family
ID=57249796
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20221474TT HRP20221474T1 (hr) | 2015-11-04 | 2016-11-03 | Cjepiva protiv virusa hepatitisa b |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US11214598B2 (hr) |
| EP (2) | EP4177348A1 (hr) |
| JP (3) | JP6914950B2 (hr) |
| KR (1) | KR20180082485A (hr) |
| CN (2) | CN115948467A (hr) |
| AU (2) | AU2016348675B2 (hr) |
| BR (1) | BR112018009032A8 (hr) |
| CA (1) | CA3003557A1 (hr) |
| DK (1) | DK3371316T3 (hr) |
| ES (1) | ES2934698T3 (hr) |
| FI (1) | FI3371316T3 (hr) |
| HK (1) | HK1255847A1 (hr) |
| HR (1) | HRP20221474T1 (hr) |
| HU (1) | HUE060648T2 (hr) |
| IL (2) | IL259077B1 (hr) |
| LT (1) | LT3371316T (hr) |
| MX (2) | MX2018005569A (hr) |
| PL (1) | PL3371316T3 (hr) |
| PT (1) | PT3371316T (hr) |
| SG (1) | SG11201803474UA (hr) |
| SI (1) | SI3371316T1 (hr) |
| WO (1) | WO2017076988A1 (hr) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| HUE054579T2 (hu) | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
| EP3218504B1 (en) | 2014-11-13 | 2020-07-22 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| CN115948467A (zh) | 2015-11-04 | 2023-04-11 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| CN108697775B (zh) | 2015-11-12 | 2023-05-09 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的沙粒病毒颗粒 |
| CN110023495A (zh) | 2016-10-14 | 2019-07-16 | 精密生物科学公司 | 对乙肝病毒基因组中的识别序列特异性的工程化大范围核酸酶 |
| JP2022010188A (ja) * | 2017-02-03 | 2022-01-14 | 株式会社三洋物産 | 遊技機 |
| JP2022010187A (ja) * | 2017-02-03 | 2022-01-14 | 株式会社三洋物産 | 遊技機 |
| US11021692B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Hepatitis B virus (HBV) vaccines and uses thereof |
| US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
| EA202091517A1 (ru) | 2017-12-19 | 2020-11-03 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Способы и устройство для доставки вакцин против вируса гепатита b (hbv) |
| WO2019195181A1 (en) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| US11142750B2 (en) | 2018-04-12 | 2021-10-12 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| EP3986455A1 (en) | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Arenavirus vectors for hepatitis b virus (hbv) vaccines and uses thereof |
| MA56523A (fr) * | 2019-06-18 | 2022-04-27 | Janssen Sciences Ireland Unlimited Co | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'anticorps anti-pd-1 ou anti-pd-l1 |
| AU2020301161B2 (en) | 2019-06-25 | 2023-10-26 | Gilead Sciences, Inc. | FLT3L-Fc fusion proteins and methods of use |
| KR20220074917A (ko) | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
| WO2021113765A1 (en) | 2019-12-06 | 2021-06-10 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
| BR112022012625A2 (pt) | 2019-12-24 | 2022-09-06 | Carna Biosciences Inc | Compostos moduladores de diacilglicerol quinase |
| CN115605493A (zh) | 2020-03-20 | 2023-01-13 | 吉利德科学公司（Us） | 4′-c-取代的-2-卤代-2′-脱氧腺苷核苷的前药及其制备和使用方法 |
| KR102375703B1 (ko) | 2020-07-28 | 2022-03-17 | 경북대학교 산학협력단 | 사물 인터넷 환경에서 CoAP 기반의 데이터 스트리밍 방법 및 통신 시스템 |
| CA3213083A1 (en) | 2021-03-23 | 2022-09-29 | Igor MATUSHANSKY | Arenaviruses used in treatments of prostate cancer |
| WO2022226242A1 (en) * | 2021-04-21 | 2022-10-27 | La Jolla Institute For Immunology | Engineered arenavirus glycoprotein compositions, methods and use thereof |
| CN113201051B (zh) * | 2021-04-27 | 2022-08-02 | 复旦大学 | 一种乙肝病毒表面蛋白突变体及其在抗乙肝病毒中的应用 |
| AU2022274607A1 (en) | 2021-05-13 | 2023-11-16 | Gilead Sciences, Inc. | COMBINATION OF A TLR8 MODULATING COMPOUND AND ANTI-HBV siRNA THERAPEUTICS |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| AU2022297373A1 (en) | 2021-06-23 | 2024-01-04 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP2024522698A (ja) | 2021-06-23 | 2024-06-21 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722840A (en) * | 1984-09-12 | 1988-02-02 | Chiron Corporation | Hybrid particle immunogens |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| JPH1084967A (ja) * | 1996-09-19 | 1998-04-07 | Fujirebio Inc | Ｂ型肝炎のｅ抗原 |
| KR100715954B1 (ko) * | 1998-12-04 | 2007-05-09 | 바이오겐 아이덱 엠에이 인코포레이티드 | 펩티드 리간드에 의하여 부착된 다중 면역원성 성분을보유한 ｈｂｖ 코어 항원 입자 |
| FR2803599B1 (fr) * | 2000-01-06 | 2004-11-19 | Inst Nat Sante Rech Med | Nouveau virus mute de l'hepatite b, ses constituants nucleiques et proteiques et leurs applications |
| WO2006125983A1 (en) * | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
| EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| EP2007765B1 (en) | 2006-03-23 | 2012-06-27 | Novartis AG | Immunopotentiating compounds |
| CN101663323A (zh) * | 2006-12-27 | 2010-03-03 | 埃默里大学 | 用于治疗传染病和肿瘤的组合物和方法 |
| EP4186978A1 (en) | 2007-12-27 | 2023-05-31 | Universität Zürich | Replication-defective arenavirus vectors |
| US10076570B2 (en) * | 2009-08-07 | 2018-09-18 | Transgene S.A. | Composition for treating HBV infection |
| RU2555346C2 (ru) | 2009-08-07 | 2015-07-10 | Трансген Са | Композиция для лечения инфекции вирусом гепатита в |
| WO2012162428A1 (en) | 2011-05-23 | 2012-11-29 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prime-boost vaccination for viral infection |
| CN110042110A (zh) | 2012-01-24 | 2019-07-23 | 桑福德健康公司 | 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 |
| EP2968506B1 (en) | 2013-03-15 | 2019-07-31 | Université de Genève | Anti-mycobacterial vaccines |
| GB201305361D0 (en) | 2013-03-25 | 2013-05-08 | Univ Edinburgh | Enhanced expression |
| HUE054579T2 (hu) | 2013-12-03 | 2021-09-28 | Hookipa Biotech Gmbh | CMV vakcinák |
| US10342861B2 (en) | 2014-05-27 | 2019-07-09 | University Of Rochester | Arenavirus vaccine |
| US9943585B2 (en) | 2014-07-30 | 2018-04-17 | University Of Rochester | Methods and compositions related to reorganization of arenavirus genome for development of novel arenavirus live-attenuated vaccines (LAV) |
| PL3198008T3 (pl) | 2014-09-22 | 2020-03-31 | Regents Of The University Of Minnesota | Układ wykorzystujący odwrotną genetykę wirusa pichinde i sposoby zastosowania |
| GB201419572D0 (en) | 2014-11-03 | 2014-12-17 | Pirbright Inst The | Virus |
| EP3218504B1 (en) * | 2014-11-13 | 2020-07-22 | Université de Genève | Tri-segmented arenaviruses as vaccine vectors |
| DE102015207036A1 (de) | 2015-04-17 | 2016-10-20 | Karl Sebastian Lang | Arenaviren zur Anwendung bei der Behandlung und/oder Vorbeugung von Tumoren sowie Verfahren zur Herstellung von Arenaviren mit (verbesserten) tumorregressiven Eigenschaften |
| CN107921117B (zh) | 2015-06-10 | 2022-06-07 | 霍欧奇帕生物科技有限公司 | Hpv疫苗 |
| EP3365005A1 (en) | 2015-10-23 | 2018-08-29 | Institut Pasteur | Recombinant mopeia virus and vaccine platform |
| CN115948467A (zh) | 2015-11-04 | 2023-04-11 | 霍欧奇帕生物科技有限公司 | 针对乙型肝炎病毒的疫苗 |
| CN108697775B (zh) | 2015-11-12 | 2023-05-09 | 霍欧奇帕生物科技有限公司 | 作为癌症疫苗的沙粒病毒颗粒 |
| US10980877B2 (en) | 2016-04-28 | 2021-04-20 | The University Of Chicago | Method for treating melanoma using lymphangiogenesis inducers and a melanoma-specific antigen |
| CN109804074B (zh) | 2016-05-18 | 2023-10-10 | 巴塞尔大学 | 作为疫苗载体的三区段pichinde病毒 |
| JP2019533690A (ja) | 2016-11-04 | 2019-11-21 | ホオキパ バイオテック ジーエムビーエイチ | 癌ワクチンとしての複製欠損性アレナウイルス粒子及び３セグメント型アレナウイルス粒子 |
| JP2020516601A (ja) | 2017-04-07 | 2020-06-11 | ホオキパ バイオテック ジーエムビーエイチ | 固形腫瘍を治療するためのアレナウイルス粒子 |
-
2016
- 2016-11-03 CN CN202211051785.6A patent/CN115948467A/zh active Pending
- 2016-11-03 PT PT167915735T patent/PT3371316T/pt unknown
- 2016-11-03 SG SG11201803474UA patent/SG11201803474UA/en unknown
- 2016-11-03 SI SI201631654T patent/SI3371316T1/sl unknown
- 2016-11-03 IL IL259077A patent/IL259077B1/en unknown
- 2016-11-03 HU HUE16791573A patent/HUE060648T2/hu unknown
- 2016-11-03 US US15/773,512 patent/US11214598B2/en active Active
- 2016-11-03 CA CA3003557A patent/CA3003557A1/en active Pending
- 2016-11-03 BR BR112018009032A patent/BR112018009032A8/pt active Search and Examination
- 2016-11-03 AU AU2016348675A patent/AU2016348675B2/en active Active
- 2016-11-03 CN CN201680077751.0A patent/CN108779472B/zh active Active
- 2016-11-03 JP JP2018541546A patent/JP6914950B2/ja active Active
- 2016-11-03 PL PL16791573.5T patent/PL3371316T3/pl unknown
- 2016-11-03 LT LTEPPCT/EP2016/076591T patent/LT3371316T/lt unknown
- 2016-11-03 EP EP22201924.2A patent/EP4177348A1/en active Pending
- 2016-11-03 IL IL314371A patent/IL314371A/en unknown
- 2016-11-03 ES ES16791573T patent/ES2934698T3/es active Active
- 2016-11-03 HR HRP20221474TT patent/HRP20221474T1/hr unknown
- 2016-11-03 EP EP16791573.5A patent/EP3371316B1/en active Active
- 2016-11-03 KR KR1020187015548A patent/KR20180082485A/ko not_active Application Discontinuation
- 2016-11-03 WO PCT/EP2016/076591 patent/WO2017076988A1/en active Application Filing
- 2016-11-03 FI FIEP16791573.5T patent/FI3371316T3/fi active
- 2016-11-03 DK DK16791573.5T patent/DK3371316T3/da active
- 2016-11-03 MX MX2018005569A patent/MX2018005569A/es unknown
-
2018
- 2018-05-03 MX MX2023013140A patent/MX2023013140A/es unknown
- 2018-11-22 HK HK18114923.3A patent/HK1255847A1/zh unknown
-
2021
- 2021-07-14 JP JP2021116562A patent/JP2021182922A/ja active Pending
- 2021-11-24 US US17/535,121 patent/US20220073568A1/en active Pending
-
2023
- 2023-01-10 AU AU2023200108A patent/AU2023200108A1/en active Pending
- 2023-10-19 JP JP2023180121A patent/JP2024010027A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20221474T1 (hr) | Cjepiva protiv virusa hepatitisa b | |
| JP2021182922A5 (hr) | ||
| JP2018536433A5 (hr) | ||
| JP6227094B2 (ja) | 複製欠損アレナウイルスベクター | |
| HRP20211015T1 (hr) | Cjepivo protiv citomegalovirusa (cmv) | |
| Kamel et al. | Foot-and-mouth disease vaccines: recent updates and future perspectives | |
| Rybicki | Plant-based vaccines against viruses | |
| Rodrigues et al. | Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology | |
| Gómez et al. | Transient expression of VP2 in Nicotiana benthamiana and its use as a plant-based vaccine against infectious bursal disease virus | |
| JP2017527557A5 (hr) | ||
| Dietzschold et al. | New approaches to the prevention and eradication of rabies | |
| Acosta-Coley et al. | Vaccines platforms and COVID-19: what you need to know | |
| EA006311B1 (ru) | Система трансфекции днк для получения инфекционного вируса гриппа | |
| Zimmer | RNA replicons-a new approach for influenza virus immunoprophylaxis | |
| Gomme et al. | Rabies virus as a research tool and viral vaccine vector | |
| García-Sastre et al. | Novel vaccine strategies against emerging viruses | |
| US20210205436A1 (en) | Recombinant mopeia virus and vaccine platform | |
| de Pinho Favaro et al. | Recombinant vaccines in 2022: a perspective from the cell factory | |
| Palese et al. | Development of novel influenza virus vaccines and vectors | |
| Weyer et al. | Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies | |
| Lawrence et al. | Comparison of heterologous prime-boost strategies against human immunodeficiency virus type 1 Gag using negative stranded RNA viruses | |
| Mathew et al. | Tobacco-based vaccines, hopes, and concerns: A systematic review | |
| Chaudhary et al. | The recent updates on approaches and clinical trials status of Covid-19 vaccines developed globally | |
| Citiulo et al. | Frontiers in the standardization of the plant platform for high scale production of vaccines | |
| RU2018103757A (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита |